Maternal and fetal outcome
Our Study
Retrospective
Di Cianni et al
.
Retrospective
[14]
Fang et al.
Retrospective
[15]
Negrato
et al.
Observational prospective
[12]
Ergman et al.
Retrospective
[16]
Number of patients on glargine
92
43
52
55
65
Intrauterine deaths
1.1 %
6 (abortions)
1 (fetal death)
0 (fetal death)
X
Preeclampsia
7.6 %
2.3%
1.9 %
1.8%
25%
Cesarean section
45%
79%
53 %
X
65 %
Maternal hypoglycemia
31%
9.3%
1.9 %
1.8%
X
Mean gestational (±SD; weeks)
36.2 ± 4.38
37.2 ± 1.5
37.8 ± 0.9
37.2± 1.4
37.3 ± 2.8
Five minute Apgar score <7
4.7%
X
2%
0
X
Macrosomia (>4000 grams)
12.3 %
21 %
X
18 %
X
Shoulder Dystocia
2.1 %
X
X
X
0%
Fetal Hypoglycemia
6.5 %
14.6%
2%
5.4%
29%
X indicates that no data is reported in those studies
Data is presented as mean plus standard deviation.
Ref [12,14-16]
Table 3
: Maternal and fetal outcomes in patients using insulin glargine during pregnancy.
